STANDEX INTERNATIONAL Expands Biotechnology Portfolio with Acquisition of Custom Biogenic Systems for $6.2 Million

☀️Trending News

STANDEX INTERNATIONAL ($NYSE:SXI), a global manufacturing company with a strong focus on technological advancements, has recently expanded its biotechnology portfolio through the acquisition of Custom Biogenic Systems. This strategic move not only strengthens Standex’s presence in the biotechnology industry but also highlights the company’s commitment to continuously expanding and enhancing its product offerings. In recent years, Standex has been actively growing its biotechnology portfolio, recognizing the immense potential and opportunities in this rapidly evolving field. The acquisition of Custom Biogenic Systems, a U.S.-based manufacturer of cryogenic equipment used in the storage and handling of biological specimens, is a strategic move that further solidifies Standex’s position in the biotechnology sector. The $6.2 million transaction was completed in cash, showcasing Standex’s strong financial position and ability to make strategic investments to drive growth. With this acquisition, Standex now has access to Custom Biogenic Systems’ advanced cryogenic storage solutions, including liquid nitrogen freezers, dewar flasks, and other accessories. These products are essential in preserving and storing biological samples used in medical research and treatments, such as stem cells, blood components, and genetic material.

By expanding its biotechnology portfolio, Standex is well-positioned to meet the increasing demand for these specialized products and capitalize on the growing biotechnology market. Moreover, this acquisition aligns with Standex’s long-term growth strategy and commitment to delivering value to its shareholders. This acquisition allows us to expand our offering of advanced solutions to customers in the biotech and medical research industries, while also enhancing our overall market position and product capabilities.” In conclusion, Standex International’s acquisition of Custom Biogenic Systems reflects the company’s commitment to continuously expanding and enhancing its product offerings in the biotechnology sector. With this strategic move, Standex is well-positioned to capture the opportunities in this rapidly growing industry and drive long-term value for its shareholders.

Share Price

On Thursday, leading global technology company STANDEX INTERNATIONAL made waves in the biotechnology industry with its latest acquisition. The company announced that it had purchased Custom Biogenic Systems for a whopping $6.2 million, expanding its already impressive biotechnology portfolio. This strategic move not only showcases STANDEX’s commitment towards growth and innovation, but also solidifies its position as a major player in the biotech space. The news of this acquisition had an immediate impact on STANDEX INTERNATIONAL’s stock, which opened at $205.71 and closed at $202.52 on Thursday. While the stock did see a slight dip of 0.74% from its previous closing price of $204.02, this can be attributed to the overall market volatility and is not reflective of the potential impact of the acquisition on the company’s future performance. So, what exactly does this acquisition mean for STANDEX INTERNATIONAL? With this acquisition, STANDEX INTERNATIONAL now gains access to a wider range of products and technologies, further enhancing its capabilities in the biotech sector. This aligns with the company’s goal of providing advanced solutions to its customers and staying ahead of the curve. Furthermore, this acquisition also brings in new revenue streams for STANDEX INTERNATIONAL. Custom Biogenic Systems has a strong customer base and a solid reputation in the industry, which will undoubtedly benefit the company’s bottom line.

In addition, STANDEX INTERNATIONAL can now offer a more comprehensive suite of biotech products and services, opening up opportunities for cross-selling and upselling to its existing customers. The CEO of STANDEX INTERNATIONAL, David Dunbar, expressed his excitement about this acquisition, stating that it perfectly aligns with the company’s long-term growth strategy. He also emphasized how Custom Biogenic Systems’ expertise and capabilities will complement their existing biotechnology portfolio and enable STANDEX to better serve its customers. With this expansion of its portfolio and capabilities, the company is well-equipped to meet the evolving needs of the biotech sector and maintain its position as a leader in the global market. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Standex International. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Standex International. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Standex International. More…

Key Ratios Snapshot

Some of the financial key ratios for Standex International are shown below. More…

Analysis

At GoodWhale, our team conducted a thorough analysis of STANDEX INTERNATIONAL‘s overall wellbeing. Our findings reveal that STANDEX INTERNATIONAL falls under the ‘rhino’ category on our Star Chart, indicating that the company has achieved moderate revenue or earnings growth. This type of company would be suitable for investors seeking steady and consistent returns. In terms of key financial metrics, STANDEX INTERNATIONAL shows strength in its assets, profitability, and dividend payout. However, its growth potential is considered medium on our scale. This suggests that while the company may not have explosive growth, it has a solid and stable foundation that can generate steady returns over time. One of the most important aspects we looked at was the company’s health score. We gave STANDEX INTERNATIONAL a high score of 9 out of 10, which is a strong indication of its financial stability. This score takes into account the company’s cash flows and debt, and we determined that STANDEX INTERNATIONAL has enough cash to pay off its debts and fund future operations. This is reassuring for investors as it minimizes the risk of default or bankruptcy. In summary, STANDEX INTERNATIONAL presents a solid investment opportunity for those seeking stable returns. Its ‘rhino’ classification on our Star Chart, along with its strong financial metrics and high health score, make it an attractive prospect for investors looking for a balanced and secure portfolio. More…

Peers

Standex International Corp has long been locked in competition with a handful of its peers, including Helios Technologies Inc, Crane Co, and Kimball Electronics Inc. All companies face the challenge of finding ways to differentiate themselves in the marketplace, while offering products and services that are in demand by customers. This competition has led to a continuously evolving landscape in which Standex International Corp has had to remain vigilant in order to remain competitive.

– Helios Technologies Inc ($NYSE:HLIO)

Helios Technologies Inc is a diversified industrial technology company that develops and manufactures industrial and energy solutions. It has a market capitalization of 1.81 billion dollars as of 2022 and has a Return on Equity of 12.31%. The company has seen steady growth in its stock price due to its focus on technological innovation and customer service. Helios Technologies Inc is focused on providing customers with high-quality products and services, and its strong financial performance has led to increased investor confidence in the company. The company’s strong ROE indicates that it is making the most of its assets and generating higher returns for its shareholders.

– Crane Co ($NYSE:CR)

Crane Co is a diversified manufacturer and service provider headquartered in Stamford, Connecticut. The company operates in five segments: Aerospace & Electronics, Fluid Handling, Engineered Materials, Merchandising Systems, and Controls. Crane Co has a market capitalization of 5.65 billion dollars as of 2022 and a Return on Equity (ROE) of 19.76%. This indicates that the company is performing well above average in terms of its ability to generate profits from shareholders’ investments. The company’s strong ROE indicates that it is well-positioned to generate returns for its investors.

– Kimball Electronics Inc ($NASDAQ:KE)

Kimball Electronics Inc is a global contract electronic manufacturing services provider. The company designs, manufactures and distributes a wide range of products for the automotive, medical, industrial, and public safety markets. As of 2022, Kimball Electronics had a market capitalization of 564.38M. This value represents the total value of the company’s outstanding shares and is often used as an indication of the company’s size. Additionally, Kimball Electronics reported a Return on Equity (ROE) of 7.77%. ROE is a measure of how efficiently a company is using its equity to generate profits, and a higher ROE indicates stronger financial performance.

Summary

Standex International Corporation has recently acquired Custom Biogenic Systems for $6.2 million. This move is expected to have a positive impact on the company’s financials and market position in the near future. Standex International is focused on strategic investments to enhance its growth and profitability.

With this move, Standex International aims to strengthen its product portfolio and expand its market reach. The company’s decision to invest in Custom Biogenic Systems is a strategic move that is expected to benefit both companies and create value for shareholders.